Lotti G, Gianrossi R
Dipartimento di Medicina Interna, Università di Genova.
Fortschr Med. 1993 Sep 30;111(27):429-32.
In a randomized double-blind study, the antihypertensive efficacy and tolerance of the imidazoline receptor agonist, moxonidine, were compared with those of the ACE inhibitor, captopril. Included in the trial were 50 ambulatory patients with mild-to-moderate hypertension, who were treated for 4 weeks with either 0.2-0.4 mg moxonidine, or 25-50 mg captopril daily. Both substances clearly reduced hypertension; no statistically significant difference was seen between the two groups. Under moxonidine, the mean blood pressure while seated decreased from 176/101 mm Hg to 155/91 mm Hg by the end of treatment; under captopril the corresponding figures were 170/99 and 150/89 mm Hg. Minor transient side effects, for the most part with a doubtful relationship to the treatment, were seen in 5 patients (20%) of the moxonidine group, and in 8 patients (32%) of the captopril group. Thus, in this study, moxonidine and captopril proved to have equivalent antihypertensive efficacy and good tolerability.
在一项随机双盲研究中，将咪唑啉受体激动剂莫索尼定的降压疗效及耐受性与血管紧张素转换酶抑制剂卡托普利进行了比较。该试验纳入了50例轻至中度高血压门诊患者，他们被随机分为两组，分别接受为期4周的治疗，一组每日服用0.2 - 0.4毫克莫索尼定，另一组每日服用25 - 50毫克卡托普利。两种药物均能显著降低血压，两组之间未观察到统计学上的显著差异。在莫索尼定治疗组，治疗结束时坐位平均血压从176/101毫米汞柱降至155/91毫米汞柱；在卡托普利治疗组，相应的血压值从170/99毫米汞柱降至150/89毫米汞柱。莫索尼定组有5例患者（20%）出现轻微短暂的副作用，大多数副作用与治疗的关系存疑；卡托普利组有8例患者（32%）出现此类情况。因此，在本研究中，莫索尼定和卡托普利被证明具有同等的降压疗效和良好的耐受性。
